Article | Published:

Regulation of apoptosis by an intrinsically disordered region of Bcl-xL

Abstract

Intrinsically disordered regions (IDRs) of proteins often regulate function upon post-translational modification (PTM) through interactions with folded domains. An IDR linking two α-helices (α1-α2) of the antiapoptotic protein Bcl-xL experiences several PTMs that reduce antiapoptotic activity. Here, we report that PTMs within the α1-α2 IDR promote its interaction with the folded core of Bcl-xL that inhibits the proapoptotic activity of two types of regulatory targets, BH3-only proteins and p53. This autoregulation utilizes an allosteric pathway whereby, in one direction, the IDR induces a direct displacement of p53 from Bcl-xL coupled to allosteric displacement of simultaneously bound BH3-only partners. This pathway operates in the opposite direction when the BH3-only protein PUMA binds to the BH3 binding groove of Bcl-xL, directly displacing other bound BH3-only proteins, and allosterically remodels the distal site, displacing p53. Our findings show how an IDR enhances functional versatility through PTM-dependent allosteric regulation of a folded protein domain.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    Babu, M. M., Kriwacki, R. W. & Pappu, R. V. Structural biology. Versatility from protein disorder. Science 337, 1460–1461 (2012).

  2. 2.

    Yeon, J. H., Heinkel, F., Sung, M., Na, D. & Gsponer, J. Systems-wide identification of cis-regulatory elements in proteins. Cell Syst. 2, 89–100 (2016).

  3. 3.

    Showalter, S. A., Bruschweiler-Li, L., Johnson, E., Zhang, F. & Brüschweiler, R. Quantitative lid dynamics of MDM2 reveals differential ligand binding modes of the p53-binding cleft. J. Am. Chem. Soc. 130, 6472–6478 (2008).

  4. 4.

    Pufall, M. A. et al. Variable control of Ets-1 DNA binding by multiple phosphates in an unstructured region. Science 309, 142–145 (2005).

  5. 5.

    Youle, R. J. & Strasser, A. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9, 47–59 (2008).

  6. 6.

    Shamas-Din, A., Kale, J., Leber, B. & Andrews, D. W. Mechanisms of action of Bcl-2 family proteins. Cold Spring Harb. Perspect. Biol. 5, a008714 (2013).

  7. 7.

    Petros, A. M. et al. Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies. Protein Sci. 9, 2528–2534 (2000).

  8. 8.

    Follis, A. V. et al. The DNA-binding domain mediates both nuclear and cytosolic functions of p53. Nat. Struct. Mol. Biol. 21, 535–543 (2014).

  9. 9.

    Follis, A. V. et al. PUMA binding induces partial unfolding within BCL-xL to disrupt p53 binding and promote apoptosis. Nat. Chem. Biol. 9, 163–168 (2013).

  10. 10.

    Maundrell, K. et al. Bcl-2 undergoes phosphorylation by c-Jun N-terminal kinase/stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Rac1. J. Biol. Chem. 272, 25238–25242 (1997).

  11. 11.

    Clem, R. J. et al. Modulation of cell death by Bcl-XL through caspase interaction. Proc. Natl. Acad. Sci. USA 95, 554–559 (1998).

  12. 12.

    Fang, G. et al. “Loop” domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis. Cancer Res. 58, 3202–3208 (1998).

  13. 13.

    Fujita, N., Nagahashi, A., Nagashima, K., Rokudai, S. & Tsuruo, T. Acceleration of apoptotic cell death after the cleavage of Bcl-XL protein by caspase-3-like proteases. Oncogene 17, 1295–1304 (1998).

  14. 14.

    Kirsch, D. G. et al. Caspase-3-dependent cleavage of Bcl-2 promotes release of cytochrome c. J. Biol. Chem. 274, 21155–21161 (1999).

  15. 15.

    Srivastava, R. K., Mi, Q. S., Hardwick, J. M. & Longo, D. L. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc. Natl. Acad. Sci. USA 96, 3775–3780 (1999).

  16. 16.

    Yamamoto, K., Ichijo, H. & Korsmeyer, S. J. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G2/M. Mol. Cell. Biol. 19, 8469–8478 (1999).

  17. 17.

    Kharbanda, S. et al. Translocation of SAPK/JNK to mitochondria and interaction with Bcl-xL in response to DNA damage. J. Biol. Chem. 275, 322–327 (2000).

  18. 18.

    Basu, A. & Haldar, S. Identification of a novel Bcl-xL phosphorylation site regulating the sensitivity of taxol- or 2-methoxyestradiol-induced apoptosis. FEBS Lett. 538, 41–47 (2003).

  19. 19.

    Du, L., Lyle, C. S. & Chambers, T. C. Characterization of vinblastine-induced Bcl-xL and Bcl-2 phosphorylation: evidence for a novel protein kinase and a coordinated phosphorylation/dephosphorylation cycle associated with apoptosis induction. Oncogene 24, 107–117 (2005).

  20. 20.

    Schmitt, E., Beauchemin, M. & Bertrand, R. Nuclear colocalization and interaction between bcl-xL and cdk1(cdc2) during G2/M cell-cycle checkpoint. Oncogene 26, 5851–5865 (2007).

  21. 21.

    Zhao, R. et al. DNA damage-induced Bcl-xL deamidation is mediated by NHE-1 antiport regulated intracellular pH. PLoS Biol. 5, e1 (2007).

  22. 22.

    Asakura, T., Maeda, K., Omi, H., Matsudaira, H. & Ohkawa, K. The association of deamidation of Bcl-xL and translocation of Bax to the mitochondria through activation of JNK in the induction of apoptosis by treatment with GSH-conjugated DXR. Int. J. Oncol. 33, 389–395 (2008).

  23. 23.

    Upreti, M. et al. Identification of the major phosphorylation site in Bcl-xL induced by microtubule inhibitors and analysis of its functional significance. J. Biol. Chem. 283, 35517–35525 (2008).

  24. 24.

    Wei, Y., Sinha, S. & Levine, B. Dual role of JNK1-mediated phosphorylation of Bcl-2 in autophagy and apoptosis regulation. Autophagy 4, 949–951 (2008).

  25. 25.

    Tamura, Y. et al. Polo-like kinase 1 phosphorylates and regulates Bcl-xL during pironetin-induced apoptosis. Oncogene 28, 107–116 (2009).

  26. 26.

    Terrano, D. T., Upreti, M. & Chambers, T. C. Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis. Mol. Cell. Biol. 30, 640–656 (2010).

  27. 27.

    Dho, S. H. et al. Control of cellular Bcl-xL levels by deamidation-regulated degradation. PLoS Biol. 11, e1001588 (2013).

  28. 28.

    Bah, N. et al. Bcl-xL controls a switch between cell death modes during mitotic arrest. Cell Death Dis. 5, e1291 (2014).

  29. 29.

    Kim, S. Y., Song, X., Zhang, L., Bartlett, D. L. & Lee, Y. J. Role of Bcl-xL/Beclin-1 in interplay between apoptosis and autophagy in oxaliplatin and bortezomib-induced cell death. Biochem. Pharmacol. 88, 178–188 (2014).

  30. 30.

    Maiuri, M. C. et al. Functional and physical interaction between Bcl-XL and a BH3-like domain in Beclin-1. EMBO J. 26, 2527–2539 (2007).

  31. 31.

    Tyler-Cross, R. & Schirch, V. Effects of amino acid sequence, buffers, and ionic strength on the rate and mechanism of deamidation of asparagine residues in small peptides. J. Biol. Chem. 266, 22549–22556 (1991).

  32. 32.

    Muchmore, S. W. et al. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 381, 335–341 (1996).

  33. 33.

    Sattler, M. et al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 275, 983–986 (1997).

  34. 34.

    Lee, E. F. et al. Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family. Cell Death Differ. 14, 1711–1713 (2007).

  35. 35.

    Yao, Y. et al. Conformation of BCL-XL upon Membrane Integration. J. Mol. Biol. 427, 2262–2270 (2015).

  36. 36.

    Yao, Y., Bobkov, A. A., Plesniak, L. A. & Marassi, F. M. Mapping the interaction of pro-apoptotic tBID with pro-survival BCL-XL. Biochemistry 48, 8704–8711 (2009).

  37. 37.

    Wysoczanski, P. et al. NMR solution structure of a photoswitchable apoptosis activating Bak peptide bound to Bcl-xL. J. Am. Chem. Soc. 134, 7644–7647 (2012).

  38. 38.

    Hagn, F., Klein, C., Demmer, O., Marchenko, N., Vaseva, A., Moll, U. M. & Kessler, H. BclxL changes conformation upon binding to wild-type but not mutant p53 DNA binding domain. J. Biol. Chem. 285, 3439–3450 (2010).

  39. 39.

    Basu, A., DuBois, G. & Haldar, S. Posttranslational modifications of Bcl2 family members–a potential therapeutic target for human malignancy. Front. Biosci. 11, 1508–1521 (2006).

  40. 40.

    Kutuk, O. & Letai, A. Regulation of Bcl-2 family proteins by posttranslational modifications. Curr. Mol. Med. 8, 102–118 (2008).

  41. 41.

    Vermes, I., Haanen, C., Steffens-Nakken, H. & Reutelingsperger, C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods 184, 39–51 (1995).

  42. 42.

    Czabotar, P. E. et al. Mutation to Bax beyond the BH3 domain disrupts interactions with pro-survival proteins and promotes apoptosis. J. Biol. Chem. 286, 7123–7131 (2011).

  43. 43.

    Domina, A. M., Vrana, J. A., Gregory, M. A., Hann, S. R. & Craig, R. W. MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene 23, 5301–5315 (2004).

  44. 44.

    Maurer, U., Charvet, C., Wagman, A. S., Dejardin, E. & Green, D. R. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol. Cell 21, 749–760 (2006).

  45. 45.

    Chipuk, J. E., Bouchier-Hayes, L., Kuwana, T., Newmeyer, D. D. & Green, D. R. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 309, 1732–1735 (2005).

  46. 46.

    Follis, A. V., Llambi, F., Merritt, P., Chipuk, J. E., Green, D. R. & Kriwacki, R. W. Pin1-induced proline ssomerization in cytosolic p53 mediates BAX activation and apoptosis. Mol. Cell 59, 677–684 (2015).

  47. 47.

    Chipuk, J. E. et al. Mechanism of apoptosis induction by inhibition of the anti-apoptotic BCL-2 proteins. Proc. Natl. Acad. Sci. USA 105, 20327–20332 (2008).

  48. 48.

    Neidhardt, F. C., Bloch, P. L. & Smith, D. F. Culture medium for enterobacteria. J. Bacteriol. 119, 736–747 (1974).

  49. 49.

    Güntert, P. Automated NMR structure calculation with CYANA. Methods Mol. Biol. 278, 353–378 (2004).

  50. 50.

    Shen, Y., Delaglio, F., Cornilescu, G. & Bax, A. TALOS+: a hybrid method for predicting protein backbone torsion angles from NMR chemical shifts. J. Biomol. NMR 44, 213–223 (2009).

  51. 51.

    Brünger, A. T. et al. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54, 905–921 (1998).

  52. 52.

    Bhattacharya, A., Tejero, R. & Montelione, G. T. Evaluating protein structures determined by structural genomics consortia. Proteins 66, 778–795 (2007).

Download references

Acknowledgements

The authors acknowledge C.R. Grace (St. Jude Children’s Research Hospital, SJCRH) for assistance with NMR experiments and B. Cassell and P. Rodrigues (SJCRH) for peptide synthesis. This work was supported by NIH R01CA082491 and 1R01GM083159 (to R.W.K.); R01GM96208 (to D.R.G.); R01 CA179087 and R35 GM118186 (to F.M.M.); National Cancer Institute Cancer Center Support grants P30CA21765 (to SJCRH) and P30CA030199 (to S.B.P.); and ALSAC (to SJCRH). A.V.F. was the recipient of the Neoma Boadway Fellowship from SJCRH.

Author information

A.V.F. designed experiments, performed experiments, analyzed data and wrote the manuscript; F.L. designed and performed cell experiments; H.K. designed experiments, performed experiments, and analyzed data; Y.Y. designed experiments, performed experiments, and analyzed data; A.H.P. designed experiments, performed experiments, and analyzed data; C.-G.P. and F.M.M. designed experiments and analyzed data; D.R.G. designed experiments and wrote the manuscript; and R.W.K. designed experiments, analyzed data and wrote the manuscript. All authors reviewed and edited the manuscript.

Competing interests

The authors declare no competing interests.

Correspondence to Richard W. Kriwacki.

Supplementary information

Supplementary Text and Figures

Supplementary Tables 1–2, Supplementary Figures 1–10

Life Sciences Reporting Summary

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading

Fig. 1: PTMs within the α1-α2 IDR of Bcl-xL downregulate its antiapoptotic function.
Fig. 2: NMR evidence of an interaction between the α1-α2 IDR and the folded core of Bcl-xL.
Fig. 3: Inhibition of the BH3-binding associated repositioning of Bcl-xL α2-α3 relative to α4-α5 by the α1-α2 IDR.
Fig. 4: Modulation of the antiapoptotic activity of Bcl-xL by mutations in the α1-α2 IDR and α2-α3.
Fig. 5: Schematic illustration of the proposed dual mechanism of allosteric regulation of Bcl-xL enabled by PTMs in the α1-α2 IDR and structural plasticity of α3.